American biotech Moderna has signed an agreement with the Ministry of Public Health to supply Qatar with its mRNA COVID-19 vaccine (mRNA-1273).
Qatar to benefit from early access to Moderna’s mRNA COVID-19 vaccine
The pioneer in messenger RNA (mRNA) therapeutics and vaccines, Moderna, revealed today it has entered into an agreement to support Qatar’s Health Ministry in its continuous efforts to secure early access to a safe and effective COVID-19 vaccine and will be supplying its vaccine candidate mRNA-1273 to the Middle Eastern country.
Through this deal, the population of Qatar will benefit from access to one of the most promising COVID-19 vaccine candidates in the world. Moderna’s vaccine candidate mRNA-1273, has generated antibodies in all patients studied in its early stage human trial. Earlier this month, the innovative biotech announced it has completed enrollment of 30,000 participants in its Phase 3 COVE study.
Stéphane Bancel, Moderna’s Chief Executive Officer stated:
“We appreciate the confidence of the Ministry of Health of Qatar in our mRNA vaccine platform and the collaboration we have had to date. We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. In parallel we are scaling up our manufacturing capability with our strategic partners, Lonza and Rovi, to address this global health emergency by delivering a safe and effective vaccine to the people of Qatar and around the world.”
Moderna has seen huge investment this year and ,perhaps, not surprisingly American stock exchange Nasdaq was one of the first to congratulate the company on reaching this important milestone:
Moderna’s COVE study
Moderna’s COVE study, to assess mRNA-1273, and which completed enrollment on October 22, is a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at the 100 µg dose level held in the United States. Participants in the study, are healthy adults who are 18 years of age and older and are at high risk of COVID-19 infection. The total length of the participation can last up to 25 months and will involve two injection visits, one on the first day and the second one month later. For more info about the study please visit: COVE Study
Scaling up manufacturing to deliver up to 1 billion doses per year
The COVID-19 vaccine candidate is not yet approved for use by any regulatory body, but Moderna is already working on scaling up global manufacturing to be able to deliver around 500 million doses annually and possibly up to 1 billion doses per year, beginning in 2021.
Moderna is furthering messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a wide spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing Moderna with the ability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
At present, Cambridge, Massachusetts headquartered, Moderna has strategic alliances for drug development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has also been named a top biopharmaceutical employer by Science for the past five years. To learn more, visit www.modernatx.com.